Radiolabeled somatostatin analogues therapy in advanced neuroendocrine tumors: A single centre experience

Journal of Oncology

Volumn , Issue , 2012, Pages

  Filice, A ^a   Fraternali, A ^a   Frasoldati, A ^a   Asti, M ^a   Grassi, E ^a   Massi, L ^a   Sollini, M ^a,b   Froio, A ^a   Erba, P A ^a,b   Versari, A ^a  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOTATATE GALLIUM GA 68; DOTATOC GALLIUM GA 68; DOTATOC LUTETIUM LU 177; DOTATOC YTTRIUM Y 90; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 5; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CHEMOEMBOLIZATION; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIALYSIS; DOSIMETRY; DRUG DISTRIBUTION; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEUROENDOCRINE TUMOR; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RADIOFREQUENCY ABLATION; THROMBOCYTOPENIA;

EID: 84866239458     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/320198     Document Type: Article

References (30)

1. Yao J. C., Hassan M., Phan A., Dagohoy C., Leary C., Mares J. E., Abdalla E. K., Fleming J. B., Vauthey J. N., Rashid A., Evans D. B., One hundred years after carcinoid: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. Journal of Clinical Oncology 2008 26 18 3063 3072 2-s2.0-46449110634 10.1200/JCO.2007.15.4377
2. Bodei L., Ferone D., Grana C. M., Peptide receptor therapies in neuroendocrine tumors. Journal of Endocrinological Investigation 2009 32 4 360 369
3. Rindi G., Klöppel G., Alhman H., Caplin M., Couvelard A., De Herder W. W., Erikssson B., Falchetti A., Falconi M., Komminoth P., Körner M., Lopes J. M., McNicol A. M., Nilsson O., Perren A., Scarpa A., Scoazec J. Y., Wiedenmann B., Arnold R., Bechstein W. O., Cadiot G., Christ E., Chung D., Delle Fave G., Ferone D., Goretzki P., Gross D., Hochhauser D., Hyrdel R., Jensen R., Kaltsas G., Keletimur F., Kianmanesh R., Knapp W., Knigge U. P., Kos-Kuda B., Kvols L., Kwekkeboom D., Lewington V., Manfredi R., Mitry E., Niederle B., Nikou G., Öberg K., O'Connor J., O'Toole D., Pauwels S., Pavel M., Plöckinger U., Ramage J., Ricke J., Ruszniewski P., Salazar R., Sauvanet A., Sevilla Garcia M. I., Steinmüller T. A., Sundin A., Taal B., Van Cutsem E., Vullierme M. P., Wildi S., Yao J. C., TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Archiv 2006 449 4 395 401 2-s2.0-33749032826 10.1007/s00428-006-0250-1 (Pubitemid 44451313)
4. Kulke M. H., Siu L. L., Tepper J. E., Fisher G., Jaffe D., Haller D. G., Ellis L. M., Benedetti J. K., Bergsland E. K., Hobday T. J., Van Cutsem E., Pingpank J., Oberg K., Cohen S. J., Posner M. C., Yao J. C., Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. Journal of Clinical Oncology 2011 29 7 934 943 2-s2.0-79952308016 10.1200/JCO.2010.33. 2056
5. Kaltsas G. A., Rockall A., Papadogias D., Reznek R., Grossman A. B., Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine tumours. European Journal of Endocrinology 2004 151 1 15 27 2-s2.0-4344679124 10.1530/eje.0.1510015 (Pubitemid 39117361)
6. Versari A., Camellini L., Carlinfante G., Frasoldati A., Nicoli F., Grassi E., Gallo C., Giunta F. P., Fraternali A., Salvo D., Asti M., Azzolini F., Iori V., Sassatelli R., Ga-68 dOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study. Clinical Nuclear Medicine 2010 35 5 321 328 2-s2.0-77951259729 10.1097/RLU.0b013e3181d6677c
7. 68Ga-DOTA-TATE. European Journal of Nuclear Medicine and Molecular Imaging 2010 37 10 2004 2010 2-s2.0-77954075605 10.1007/s00259-010-1512-3
8. Naswa N., Sharma P., Kumar A., Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study. American Journal of Roentgenology 2011 197 5 1221 1228
9. 3]octreotide: peptides for somatostatin receptor-targeted scintigraphy and radionuclide therapy. Nuclear Medicine Communications 1998 19 3 283 288 2-s2.0-0031596355 (Pubitemid 28198201)
10. Slooter G. D., Breeman W. A., Marquet R. L., Anti-proliferative effect of radiolabeled octreotide in a metastases model in rat liver. International Journal of Cancer 1999 81 767 771 (Pubitemid 29214388)
11. Virgolini I. J., Gabriel M., von Guggenberg E., Putzer D., Kendler D., Decristoforo C., Role of radiopharmaceuticals in the diagnosis and treatment of neuroendocrine tumours. European Journal of Cancer 2009 45 supplement 1 274 279 2-s2.0-70349157203 10.1016/S0959-8049(09)70042-5
12. Bombardieri E., Virgolini I., Diagnosis and therapy of neuroendocrine tumours. Quarterly Journal of Nuclear Medicine and Molecular Imaging 2010 54 1 1 2 2-s2.0-77952534978
13. 177Lu-DOTATATE: which is a better therapy option? European Journal of Nuclear Medicine and Molecular Imaging 2011 38 10 1788 1797 2-s2.0-79955561898 10.1007/s00259-011-1833-x
14. Ambrosini V., Fani M., Fanti S., Radiopeptide imaging and therapy in Europe. Journal of Nuclear Medicine 2011 52 supplement 2 42S 55S
15. Grassi E., Sghedoni R., Asti M., Fioroni F., Salvo D., Borasi G., Radiation protection in 90Y-labelled DOTA-D-Phe1-Tyr3-octreotide preparations. Nuclear Medicine Communications 2009 30 2 176 182 2-s2.0-58549092837 10.1097/MNM.0b013e328318effb
16. 177Lu DOTA-NOC. Cancer Biotherapy and Radiopharmaceuticals 2007 22 3 406 416 2-s2.0-34447527563 10.1089/cbr.2006.325 (Pubitemid 47067899)
17. 3+ Nuclear Medicine and Biology 2004 31 6 821 824 2-s2.0-3042714753 10.1016/j.nucmedbio. 2004.03.008 (Pubitemid 38887766)
18. Decristoforo C., Knopp R., von Guggenberg E., Rupprich M., Dreger T., Hess A., Virgolini I., Haubner R., A fully automated synthesis for the preparation of 68Ga-labelled peptides. Nuclear Medicine Communications 2007 28 11 870 875 2-s2.0-34848920415 10.1097/MNM.0b013e3282f1753d (Pubitemid 47494113)
19. 68Ga-DOTATOC. Nuclear Medicine and Biology 2008 35 6 721 724 2-s2.0-48349142477 10.1016/j.nucmedbio.2008.04.006
20. Stabin M. G., Sparks R. B., Crowe E., OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. Journal of Nuclear Medicine 2005 46 6 1023 1027 2-s2.0-23044470017 (Pubitemid 43733519)
21. 90Y-DOTATOC. European Journal of Nuclear Medicine 1999 26 8 877 886 2-s2.0-0032764336 10.1007/s002590050462 (Pubitemid 29397000)
22. National Cancer Institute, CTEP: NCI Guidance on CTC Terminology Applications 2006 Bethesda, Md, USA National Cancer Institute
23. 90Y- labeled somatostatin analogs. Journal of Nuclear Medicine 2005 46 supplement 1 13S 17S 2-s2.0-14844350129 (Pubitemid 47619014)
24. Gabriel M., Andergassen U., Putzer D., Kroiss A., Waitz D., Von Guggenberg E., Kendler D., Virgolini I. J., Individualized peptide-related- radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients. Quarterly Journal of Nuclear Medicine and Molecular Imaging 2010 54 1 92 99 2-s2.0-77952487451
25. 177Lu-DOTATATE: the IEO phase I-II study. European Journal of Nuclear Medicine and Molecular Imaging 2011 38 12 2125 2135
26. 3]octreotate: toxicity, efficacy, and survival. Journal of Clinical Oncology 2008 26 13 2124 2130 2-s2.0-43749091955 10.1200/JCO.2007.15.2553
27. Glinicki P., Jeske W., Chromogranin A (CgA)the influence of various factors in vivo and in vitro, and existing disorders on it's concentration in blood. Endokrynologia Polska 2010 61 4 384 387 2-s2.0-77957260835
28. Ito T., Igarashi H., Jensen R. T., Serum pancreastatin: the long sought universal, sensitive, specific tumor marker for neuroendocrine tumors? Pancreas 2012 41 4 505 507
29. 177Lu-DOTATATE: the role of associated risk factors. European Journal of Nuclear Medicine and Molecular Imaging 2008 35 10 1847 1856 2-s2.0-52449111580 10.1007/s00259-008-0778-1
30. 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. Journal of Nuclear Medicine 2005 46 supplement 1 99S 106S 2-s2.0-14844354088 (Pubitemid 47619025)